%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
81 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T19:32:42Z
2024-03-29T02:59:11-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T02:59:11-07:00
application/pdf
Heather
2000-1162.feb
uuid:d86942cf-1dd1-11b2-0a00-a008271d5700
uuid:d86942d2-1dd1-11b2-0a00-bf0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
99 0 obj
[103 0 R]
endobj
100 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:2)Tj
0 Tw -46.2952 -0.0313 Td
(330)Tj
ET
0 0 0 0 scn
/GS0 gs
100.33 58.07 407.5 -10.83 re
f*
0.5 w
100.33 58.07 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.3027 Tw 10 0 0 10 54 713.1616 Tm
(applied, most often through confusion or an inaccurate)Tj
0.02499 Tw 0 -1.2 TD
(knowledge of the 2 concepts, diagnosis and classification.)Tj
0.05611 Tw 1.2 -1.2 Td
(Classification criteria use the \223gold standard\224 to include)Tj
0.12131 Tw -1.2 -1.2 Td
(patients in scientific studies)Tj
0 Tw 6.5 0 0 6.5 168.4391 680.4615 Tm
(14)Tj
0.12131 Tw 10 0 0 10 178.6526 677.1616 Tm
(in order to ensure compara-)Tj
0.1875 Tw -12.4653 -1.2 Td
(bility in the identification and standardization of patients)Tj
0.2253 Tw T*
[(with related pathologies. However)39.8 (, they were not devel-)]TJ
0.07829 Tw T*
(oped, nor are they suitable, for establishing a reliable clin-)Tj
0.19859 Tw T*
(ical diagnosis, which can only be reached after a highly)Tj
0.10831 Tw T*
(complex cognitive process very often dependent on subtle)Tj
0.16451 Tw T*
(findings, but never on just a few criteria. Diagnostic and)Tj
-0.00011 Tc 0.02499 Tw T*
[(classification criteria are essentially dif)17.7 (ferent.)]TJ
0 Tc 0.27969 Tw 1.2 -1.2 Td
[(Despite their excellent sensitivity and specificity)64.9 (, the)]TJ
-0.00011 Tc 0.05389 Tw -1.2 -1.2 Td
(ESSG criteria were developed primarily as a \223set of classi-)Tj
0 Tc 0.06731 Tw T*
(fication criteria,\224 an instrument for clinical use intended to)Tj
0.2449 Tw T*
(help one decide whether a patient with a given clinical)Tj
-0.00011 Tc 0.06129 Tw T*
[(picture can be classified as the carrier of a SpA)-256.4 (even if the)]TJ
0 Tc -0.0345 Tw T*
(specific underlying nosological entity cannot be identified at)Tj
-0.00011 Tc 0.257 Tw T*
[(the time. )17.8 (The usefulness of these criteria for diagnostic)]TJ
0.0368 Tw T*
(purposes has been discussed)Tj
0 Tc 0 Tw 6.5 0 0 6.5 168.6737 500.4616 Tm
(15)Tj
-0.00011 Tc 0.0368 Tw 10 0 0 10 175.1737 497.1616 Tm
[(. )17.8 (The proven success of these)]TJ
0 Tc 0.1132 Tw -12.1174 -1.2 Td
(essentially classifying criteria and their widespread accep-)Tj
0 Tw T*
(tance)Tj
-0.00011 Tc 6.5 0 0 6.5 75.0937 476.4616 Tm
(4-7)Tj
0 Tc 0.1071 Tw 10 0 0 10 87.3278 473.1616 Tm
[(have led to their misuse as diagnostic criteria. )17.8 (W)79.8 (e)]TJ
0.3165 Tw -3.3328 -1.2 Td
(examined the characteristics of the ESSG classification)Tj
0.0874 Tw T*
(criteria obtained in France and Spain; for this purpose, we)Tj
-0.02139 Tw T*
(applied the criteria to the patients in both studies a posteriori)Tj
-0.0361 Tw T*
[(and considered the prevalence of SpA)-159 (in the 2 environments.)]TJ
0.0105 Tw T*
[(The dif)17.8 (ferences between the 2 populations suggest the pres-)]TJ
0.073 Tw T*
[(ence of dif)17.8 (ferences in the pathological spectrum dealt with)]TJ
0.2032 Tw T*
(at hospital rheumatology outpatient departments in the 2)Tj
0.1667 Tw T*
[(countries \227 although the interobserver dif)17.8 (ferences in the)]TJ
-0.00011 Tc -0.03391 Tw T*
(interpretation of what constitute signs and symptoms of SpA)Tj
0 Tc 0.132 Tw T*
[(may also contribute to the dif)17.8 (ferences observed, since the)]TJ
-0.00011 Tc 0.2141 Tw T*
[(interobserver error in determining SpA/non\226SpA)-409.3 (has not)]TJ
0.02499 Tw T*
(been assessed.)Tj
0 Tc 0.04739 Tw 1.2 -1.2 Td
[(From the study)64.9 (, a projection was developed on the basis)]TJ
0.1463 Tw -1.2 -1.2 Td
[(of the actual prevalence of SpA)-341.4 (in each specific environ-)]TJ
0.0101 Tc 0.3649 Tw T*
(ment \(private practice, outpatient department, patients)Tj
0 Tc 0.08411 Tw T*
(admitted to hospital\) that should be of use for future diag-)Tj
-0.00011 Tc 0 Tw T*
(noses.)Tj
0 Tc 0.01871 Tw 1.2 -1.2 Td
[(For a prevalence of SpA)-213.9 (above 10% in the environments)]TJ
-0.002 Tw -1.2 -1.2 Td
(considered, a patient in Group 4 can be diagnosed with SpA)Tj
0.011 Tw T*
(with an error less than 20%; on the other hand, reaching the)Tj
0.10091 Tw T*
(same conclusion for a patient in Group 3 requires that the)Tj
0.0726 Tw T*
(prevalence be higher than 30%. For Spanish rheumatology)Tj
0.1149 Tw T*
(services, the likelihood of a patient under 35 years of age)Tj
0.04311 Tw T*
[(\(SpA)-238.2 (prevalence = 48.9%\) in Group 3 actually having SpA)]TJ
0.0191 Tw T*
(will be 87% \(95% CI 84\22690%\); that of a patient in Group 4)Tj
0.07899 Tw T*
(will be 98%. On the other hand, for French patients of the)Tj
-0.0145 Tw T*
(same age classified in Groups 3 and 4, the likelihood will be)Tj
-0.00011 Tc -0.0174 Tw T*
(70% \(95% CI 64\22695%\) and 94% \(95% CI 91\22696%\), respec-)Tj
0 Tc 0.02901 Tw T*
(tively \(the prevalence among the French population studied)Tj
-0.00011 Tc 0.02499 Tw T*
(was 22.5%\).)Tj
0.005 Tc 0.37 Tw 27.6 60 Td
(These diagnostic tools should be applied to newly)Tj
-0.00011 Tc -0.0015 Tw -1.2 -1.2 Td
(referred patients, as it is necessary to know the pretest prob-)Tj
0 Tc 0.0569 Tw T*
(ability \(or prevalence\) for age and sex in order to calculate)Tj
0.10249 Tw T*
[(the posttest probability)64.9 (. From the foregoing it follows that)]TJ
-0.00011 Tc 0.0766 Tw T*
(for ESSG criteria to be useful as a diagnostic aid for SpA,)Tj
0 Tc 0.0853 Tw T*
(appropriate epidemiological data for each major rheumatic)Tj
0.02499 Tw T*
(disease in the environment concerned must be available.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0.0607 Tw 8 0 0 8 318 607.1616 Tm
[(The authors are grateful to Prof. Bernard )54.8 (Amor)39.7 (, Prof. Maxime Dougados,)]TJ
0 Tc 0.01781 Tw 0 -1.25 TD
[(and Dr)54.9 (. )17.7 (V)111.1 (eronique Listrat for their collaboration with data from the French)]TJ
0.02499 Tw T*
[(study)65 (, and Justin Spoliar for technical assistance.)]TJ
/TT2 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 563.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 325 553.1616 Tm
[(1.)-875 (Dougados M, van der Linden SM, Juhlin R, et al. )17.8 (The European)]TJ
1.675 -1.25 Td
(Spondylarthropathy Study Group preliminary criteria for the)Tj
T*
[(classification of spondylarthropathy)64.9 (. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1991;34:1218-27.)Tj
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Dougados M. How to diagnose spondylarthropathy? [editorial].)]TJ
1.675 -1.25 Td
[(Clin Exp Rheumatol 1993;1)36.9 (1:1-3.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Amor B, Dougados M, Listrat )17.7 (V)129.2 (, et al. Evaluation des crit\350res des)]TJ
1.675 -1.25 Td
(spondylarthropathies d\264Amor et de l\264European Spondylarthropathy)Tj
T*
[(Study Group \(ESSG\). )54.8 (Ann Med Interne 1991;142:85-9.)]TJ
-1.675 -1.25 Td
[(4.)-875 (Collantes E, Cisnal )54.8 (A, Mu\361oz E. )54.8 (Assessment of two systems of)]TJ
1.675 -1.25 Td
(spondyloarthropathy diagnostic and classification criteria \(Amor)Tj
T*
[(and ESSG\) by a Spanish multicenter study)64.9 (. J Rheumatol)]TJ
0 Tw T*
(1995;22:246-51.)Tj
0.0249 Tw -1.675 -1.25 Td
[(5.)-875 (Boyer GS, )17.7 (T)69.8 (emplin DW)91.8 (, Goring )17.7 (WP)110.8 (. Evaluation of the European)]TJ
1.675 -1.25 Td
(Spondylarthropathy Study Group preliminary classification criteria)Tj
T*
[(in )54.9 (Alaskan Eskimo populations. )54.9 (Arthritis Rheum 1993;36:534-8.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Ertuk M, )54.8 (Alaca R, )17.7 (T)69.7 (osun E, Duruoz MT)73.9 (. Evaluation of the )54.8 (Amor)]TJ
1.675 -1.25 Td
(and ESSG classification criteria for spondylarthropathies in a)Tj
0 Tc T*
[(T)34.9 (urkish population. Rev Rhum [Engl Ed] 1997;64:293-300.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Baddoura R, )54.8 (A)91.9 (wada H, Okais J, Habis )17.7 (T)73.9 (,)-0.1 ( )54.8 (Attoui S, )54.8 (Abi Saab M.)]TJ
0 Tc 1.675 -1.25 Td
[(V)111.1 (alidation of the European Spondylarthropathy Study Group and B.)]TJ
T*
(Amor criteria for spondylarthropathies in Lebanon. Rev Rhum)Tj
T*
([Engl Ed] 1997;64:459-64.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Dougados M. Diagnostic features of ankylosing spondylitis)]TJ
0 Tc 1.675 -1.25 Td
([editorial]. Br J Rheumatol 1995;34:301-5.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Amor B, Dougados M, Listrat )17.7 (V)129.1 (,)-0.1 ( et al. )54.8 (Are classification criteria for)]TJ
0 Tc 1.675 -1.25 Td
(spondyloarthropathy useful as diagnostic criteria? Rev Rhum [Engl)Tj
T*
(Ed] 1995;62:10-5.)Tj
-2.175 -1.25 Td
[(10.)-875 (Gordis L. )17.7 (The role of epidemiology in the study of rheumatic)]TJ
2.175 -1.25 Td
(diseases. In: Lawrence RC, Schulmann LE, editors. Epidemiology)Tj
-0.00011 Tc T*
[(of the rheumatic diseases. New )36.8 (Y)100 (ork: Gower Medical Publishing)]TJ
0 Tc T*
(Ltd.; 1984.)Tj
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Khan MA. )54.8 (A)-219.8 (worldwide overview: the epidemiology of HLA-B27)]TJ
2.1381 -1.25 Td
[(and associated spondylarthritides. In: Calin )54.8 (A, )17.7 (T)69.8 (aurog JD, editors.)]TJ
-0.00011 Tc T*
(The spondylarthritides. Oxford: Oxford University Press; )Tj
0 Tc 0 Tw T*
(1998:17-26.)Tj
0.0249 Tw -2.175 -1.25 Td
[(12.)-875 (Arnett FC. )54.8 (Ankylosing spondylitis. In: Koopman )17.7 (WJ, editor)54.9 (.)]TJ
2.175 -1.25 Td
[(Arthritis and allied conditions. 13th ed. Baltimore: )17.8 (W)39.8 (illiams &)]TJ
T*
[(W)39.8 (ilkins; 1997:1)36.9 (197-209.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Saraux )54.8 (A, Guedes C, )54.8 (Allain J, et al. Prevalence of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis and spondyloarthropathy in Brittany)64.9 (, France. J Rheumatol)]TJ
0 Tw T*
(1999;26:2622-7.)Tj
0.0249 Tw -2.175 -1.25 Td
[(14.)-875 (Arnett FC. Revised criteria for the classification of rheumatoid)]TJ
2.175 -1.25 Td
(arthritis. Bull Rheum Dis 1989;38:1-6.)Tj
-2.175 -1.25 Td
[(15.)-875 (Dougados M. Classification and diagnosis of seronegative)]TJ
2.175 -1.25 Td
(spondylarthropathies. Scand J Rheumatol 1999;28:336-9.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
70 0 obj
<>
endobj
86 0 obj
<>
endobj
49 0 obj
<>
endobj
53 0 obj
<>
endobj
20 0 obj
<>
endobj
25 0 obj
<>
endobj
26 0 obj
<>stream
HdVpTs͋XbHvdM IA.